Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

119.12 -0.66 (-0.55%)

Streaming Delayed Price Updated: 3:13 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

68 69 Next >

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

November 12, 2024

From Gilead Sciences, Inc.

Via Business Wire

3 Spectacular High-Yield Dividend Stocks to Buy in November ↗

November 10, 2024

High yields aren't a warning indicator with these three stocks.

Via The Motley Fool

Gilead Sciences to Present at Upcoming Investor Engagements

November 08, 2024

From Gilead Sciences, Inc.

Via Business Wire

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

3 Healthcare Stocks For Long-Term Growth And Dividends ↗

November 07, 2024

Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.

Via Talk Markets

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

November 06, 2024

Via Benzinga

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗

November 08, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Via Investor's Business Daily

Topics Economy Government

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook ↗

November 07, 2024

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence.

Via Benzinga

Topics Earnings

Gilead Sciences's Earnings: A Preview ↗

November 05, 2024

Via Benzinga

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

October 31, 2024

Via ACCESSWIRE

Peering Into Gilead Sciences's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday? ↗

November 07, 2024

After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely...

Via Benzinga

Topics Economy

Gilead’s Stock Surge: What’s Fueling the Momentum?

November 07, 2024

Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.

Via MarketBeat

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

November 07, 2024

From Gilead Sciences, Inc.

Via Business Wire

Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗

October 21, 2024

Via Benzinga

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript ↗

November 06, 2024

GILD earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Gilead Sciences Announces Third Quarter 2024 Financial Results

November 06, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales ↗

November 06, 2024

The company also raised its earnings and sales guidance for the year.

Via Investor's Business Daily

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

November 05, 2024

From Gilead Sciences, Inc.

Via Business Wire

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

October 22, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks ↗

October 21, 2024

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success...

Via Benzinga

Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 21, 2024

Via Benzinga

This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

October 21, 2024

Via Benzinga

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

October 19, 2024

From Gilead Sciences, Inc.

Via Business Wire

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗

October 18, 2024

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.